Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 6, 2019

iRhythm, Verily teams up to develop diagnostic tools for AFib

iRhythm Technologies has collaborated with Alphabet’s health venture Verily to develop new technology for screening, diagnosing and managing atrial fibrillation (AFib) patients.

iRhythm Technologies has collaborated with Alphabet’s health venture Verily to develop new technology for screening, diagnosing and managing atrial fibrillation (AFib) patients.

AFib is a common form of irregular heart rhythm that can multiply a person’s risk of severe or fatal stroke.

The partnership will leverage iRhythm’s AI-based diagnosis of arrhythmia, along with Verily’s analytics of health data to find a solution for AFib, which affects around 10 million Americans.

The main focus of the collaboration is to find a solution for asymptomatic AFib, in patients who are unaware they have the condition.

Under the terms of collaboration, both companies will work towards a solution that can provide early warnings, which can help to identify and manage the patient before the onset of a stroke.

Verily chief medical and scientific officer Dr Jessica Mega said: “With the high prevalence of cardiovascular-related health issues, we have an opportunity to not only improve how we diagnose, manage and monitor conditions like atrial fibrillation but also develop patient-centric solutions that could ultimately prevent serious cardiac events.”

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

iRhythm CEO and president Kevin King said: “Verily’s patient-centric approach to disease management and advanced hardware capabilities will prove critical in providing patients and providers with the tools needed to increase the efficiency of heart healthcare.”

According to the agreement, Verily will receive an upfront payment of $5m from iRhythm. The deal also involves potential milestone payments of up to $12.5m.

Last year, Janssen Pharmaceutical announced the encouraging one-year results from the mSToPS clinical trial that evaluated the wearable continuous electrocardiogram (ECG) monitoring iRhythm ZIO XT Patch to identify AFib.

The single-use, 14-day wearable sensor is designed to monitor and retain data from the continuous ECG of the user for up to two weeks.

Trial data revealed that the patch could identify those with AFib earlier and more efficiently than standard care. The home-based trial took place in alliance with Scripps Translational Science Institute (STSI), Aetna and iRhythm Technologies.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU